A Detailed Overview of Rivaroxaban Impurities: EP, USP, and Global Guidelines

At Chemicea Pharmaceutical, we specialize in delivering high-quality pharmaceutical reference standards, including a comprehensive range of Rivaroxaban impurities. These impurities are synthesized and characterized in compliance with international pharmacopeial guidelines such as the European Pharmacopoeia (EP), United States Pharmacopeia (USP), and other global standards.

Rivaroxaban, a widely prescribed anticoagulant, plays a crucial role in preventing and treating blood clots. Ensuring the purity, stability, and efficacy of Rivaroxaban is essential, and the ability to identify and manage impurities is a key factor in maintaining product quality and regulatory compliance.

What Are Rivaroxaban Impurities?

Rivaroxaban impurities refer to substances that may form during the manufacturing, storage, or degradation of the drug. These impurities can affect the drug’s purity and efficacy. They must be identified, controlled, and minimized to meet pharmacopeial standards.

How Rivaroxaban Impurities Impact Pharmaceutical Quality

Impurities in Rivaroxaban can arise from several sources, such as synthesis by-products, degradation products due to environmental factors, or process inconsistencies. Proper identification and management of these impurities are vital for maintaining the drug’s quality, safety, and efficacy, ensuring compliance with EP, USP, and other regulatory standards.

Rivaroxaban Structure

Rivaroxaban Chemical Details

• CAS Number: 366789-02-8
• Chemical Formula: C19H18ClN3O5S
• Molecular Weight: 435.88 g/mol
• IUPAC Name: 5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide
• Synonyms:
• Xarelto
• Rivaxan
• Rivoron

These chemical details form the foundation for understanding Rivaroxaban's synthesis, stability, and potential impurities, ensuring compliance with pharmacopeial standards.

The Chemistry of Rivaroxaban

Rivaroxaban is a direct oral anticoagulant that inhibits factor Xa, reducing the risk of blood clot formation. Its complex chemical structure includes a morpholine ring and oxazolidine core, which makes it highly effective in inhibiting blood clotting. However, this structure also presents challenges in managing potential impurities during the drug's synthesis and storage. Understanding the chemistry of Rivaroxaban is key to identifying impurities and ensuring that the drug meets global regulatory guidelines.

Pharmaceutical Applications of Rivaroxaban

• Primary Use: Rivaroxaban is used to prevent and treat deep vein thrombosis (DVT), pulmonary embolism (PE), and reduce the risk of stroke in patients with atrial fibrillation.
• Off-Label Uses: It has also been explored for its potential in treating other thrombotic disorders.

The purity and stability of Rivaroxaban are vital to its success in these applications. Controlling impurities ensures that Rivaroxaban remains safe, effective, and compliant with global pharmacopeial standards.

Rivaroxaban and Its Impurities Tree Diagram

Understanding Rivaroxaban Impurities

Impurities in Rivaroxaban can be classified into three main categories:

• Degradation Impurities: Formed when Rivaroxaban is exposed to heat, light, or pH changes during storage.
• Process Impurities: By-products that result from incomplete reactions or side reactions during synthesis.
• Potential Impurities: Hypothetical impurities predicted based on the synthetic pathway and degradation mechanisms.

Managing these impurities is essential for maintaining the stability and efficacy of the drug. At Chemicea Pharmaceutical, we offer high-quality reference standards to help pharmaceutical companies ensure compliance with EP, USP, and global guidelines.

Key Rivaroxaban Impurities Offered by Chemicea

At Chemicea Pharmaceutical, we provide an extensive range of Rivaroxaban impurities. These impurities are critical for quality control, stability testing, and method development in pharmaceutical research. Below is a list of key Rivaroxaban impurities, arranged alphabetically:

These impurities are monitored and controlled to ensure product consistency and meet stringent regulatory standards.

Classification and Description of Rivaroxaban Impurities

1. Rivaroxaban EP Impurity A (CAS No. 865479-71-6)
• Type: Process Impurity
• Description: A by-product of the synthesis process, typically formed due to incomplete reactions.
• Role: Important in process control to ensure efficient and consistent production.
2. Rivaroxaban EP Impurity B (CAS No. 1429334-00-8)
• Type: Degradation Impurity
• Description: Forms when Rivaroxaban is exposed to environmental factors like light and heat.
• Role: Used in stability testing to ensure product efficacy over time.
3. Rivaroxaban EP Impurity D (CAS No. 1365267-35-1)
• Type: Potential Impurity
• Description: A predicted impurity that may form under specific synthetic conditions.
• Role: Important in method development for impurity profiling.
4. Rivaroxaban EP Impurity E (CAS No. 1415566-28-7)
• Type: Process Impurity
• Description: A by-product formed due to variations in reaction conditions.
• Role: Monitored for process optimization.
5. Rivaroxaban EP Impurity F (CAS No. 24065-33-6)
• Type: Degradation Impurity
• Description: Forms under oxidative conditions, such as exposure to air or light over time.
• Role: Used in stability testing to assess the impact of oxidation on Rivaroxaban's shelf life.
6. Rivaroxaban EP Impurity G  (CAS No. 446292-08-6)
• Type: Process Impurity
• Description: A by-product that can form due to variations in reaction temperature or catalyst quality during synthesis.
• Role: Important for ensuring batch-to-batch consistency during manufacturing.
7. Rivaroxaban EP Impurity H (CAS No. 1770812-37-7)
• Type: Potential Impurity
• Description: Hypothetically predicted impurity based on the synthetic pathway of Rivaroxaban.
• Role: Monitored as part of comprehensive impurity profiling to ensure regulatory compliance.
8. Rivaroxaban EP Impurity I (CAS No. 1151893-81-0)
• Type: Process Impurity
• Description: A by-product that forms during synthesis due to incomplete reactions or impurities in starting materials.
• Role: Ensures the purity of Rivaroxaban by maintaining tight control over synthesis conditions.
9. Rivaroxaban EP Impurity J (CAS No. 1632463-24-1)
• Type: Degradation Impurity
• Description: Forms when Rivaroxaban is exposed to varying pH levels, particularly during storage in different formulation matrices.
• Role: Assessed during stability studies to ensure Rivaroxaban's efficacy and safety over its shelf life.

How Chemicea Helps Ensure Quality

At Chemicea Pharmaceutical, we provide certified reference standards for Rivaroxaban impurities, helping pharmaceutical companies maintain regulatory compliance and meet the highest quality standards. By utilizing our expertise in impurity profiling and synthesis, we ensure that your products are safe, effective, and fully compliant with international standards.

Conclusion and Call to Action

Managing Rivaroxaban impurities is crucial for maintaining the quality, safety, and efficacy of pharmaceutical products. Chemicea Pharmaceutical provides the expertise and certified reference standards needed to support your quality control and regulatory compliance efforts.